REPL
$7.00
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intend...
Recent News
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
MLYS shares rise after the FDA accepts NDA for lorundrostat to treat hypertension. A decision from the regulatory body is due on Dec. 22, 2026.
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
Biotech Stocks Rally on Departure of Polarizing FDA Official
Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division and blocked several rare-disease drugs from receiving accelerated approval. Prasad’s stance had weighed heavily on the stocks of companies developing the drugs. Now those stocks are rallying after FDA Commissioner Marty Makary said Friday in an interview that Prasad will be departing at the end of April.
Mirum Completes Enrollment & Screening in Liver Disease Studies
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.